Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
Department of Veterans Affairs |
---|---|
Information provided by: | Department of Veterans Affairs |
ClinicalTrials.gov Identifier: | NCT00018148 |
Treatment of smokers with a tricyclic antidepressant, nortriptyline, can reduce tobacco withdrawal symptoms and increases long term cessation rates when combined with transdermal nicotine and a behavioral cessation programs.
The study is a placebo-controlled, randomized, parallel group trial in which smokers aged 18-70 will be subject to the combination of oral and patch treatments.
Condition | Intervention | Phase |
---|---|---|
Smoking |
Drug: nortriptyline |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Efficacy Study |
Official Title: | Combined Nortriptyline and Transdermal Nicotine for Smoking Cessation |
Ages Eligible for Study: | 18 Years to 70 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Study ID Numbers: | ADRD-006-97F |
Study First Received: | July 3, 2001 |
Last Updated: | January 20, 2009 |
ClinicalTrials.gov Identifier: | NCT00018148 History of Changes |
Health Authority: | United States: Federal Government |
smoking cessation |
Nicotine polacrilex Smoking Neurotransmitter Agents Adrenergic Agents Nicotine |
Nortriptyline Psychotropic Drugs Antidepressive Agents Antidepressive Agents, Tricyclic |
Neurotransmitter Agents Neurotransmitter Uptake Inhibitors Adrenergic Agents Molecular Mechanisms of Pharmacological Action Adrenergic Uptake Inhibitors Physiological Effects of Drugs Psychotropic Drugs Pharmacologic Actions |
Antidepressive Agents, Tricyclic Smoking Habits Therapeutic Uses Nortriptyline Central Nervous System Agents Antidepressive Agents |